SYLVANT® Patient Support

Supporting Treatment

Helping you help your patients get started with the SYLVANT® treatment you prescribed and supporting them along the way

We are committed to supporting you and your patients. Click here for the Janssen CarePath Resource Guide.

We understand how important it is for your patients to take their SYLVANT® medication just as you've prescribed. Janssen CarePath provides ongoing support to help your patients stay on track with their SYLVANT® treatment.

Janssen CarePath Account

Your patients can Sign Up or Log In to their personal Janssen CarePath Account so they can learn about support resources, get answers to questions about their insurance coverage, find affordability programs, and more.

Support

Janssen CarePath offers additional support to keep your patients informed about SYLVANT® and provides resources to help them stay on track with their SYLVANT® treatment as you've prescribed.

Tools to help your patients track and meet their health and wellness goals

Care4Today® Connect is a helpful medication and appointment tracking and reminder tool designed to empower users to take an active role in their own health care. This application can enable users to track key health measures, providing support and motivation in between doctor visits in the following ways:

  • Delivers medication and appointment reminders
  • Enables users to record information such as exercise, etc.
  • Users can share self-reported data with healthcare professionals

Janssen Biotech, Inc., the maker of SYLVANT®, does not endorse and is not responsible for the content of the Web site listed below, or the services provided by this organization. Clicking on the link below will take you to a Web site to which our Privacy Policy does not apply. We encourage you to read the Privacy Policy of every Web site you visit.

Advocacy Connector

AdvocacyConnector.com
This Web site connects patients and caregivers to national and state-specific advocacy groups relevant to oncology.

Indication

SYLVANT® (siltuximab) is indicated for the treatment of patients with Multicentric Castleman's Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Limitation of Use. SYLVANT® was not studied in patients with MCD who are HIV-positive or HHV-8 positive because SYLVANT® did not bind to virally produced IL-6 in a nonclinical study.

Important Safety Information For SYLVANT®

CONTRAINDICATIONS – Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT®. Hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab.

Concurrent Active Severe Infections – Do not administer to patients with severe infections until the infection resolves. SYLVANT® may mask signs and symptoms of acute inflammation including suppression of fever and of acute phase reactants such as C-reactive protein (CRP). Monitor patients closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT® until the infection resolves.

Vaccinations – Do not administer live vaccines to patients receiving SYLVANT® because interleukin-6 (IL-6) inhibition may interfere with the normal immune response to new antigens.

Infusion Related Reactions and Hypersensitivity – SYLVANT® may cause infusion related reactions and anaphylaxis. In clinical trials, one out of approximately 945 patients experienced an anaphylactic reaction. Infusion related reactions were reported in 5.1% of 254 patients. Two (0.8%) were Grade 3 or higher, and 1 (0.4%) was serious; none were fatal. Symptoms of infusion reactions consisted of back pain, chest pain or discomfort, nausea and vomiting, flushing, erythema, and palpitations.

In long-term treatment of MCD patients with siltuximab at the recommended dosage of 11 mg/kg every 3 weeks, infusion related reactions or hypersensitivity reactions occurred at a frequency of 6.3% (1.3% for severe reactions).

Stop the infusion if the patient develops signs of anaphylaxis. Discontinue further therapy with SYLVANT®.

Stop the infusion if the patient develops a mild to moderate infusion reaction. If the reaction resolves, the infusion may be restarted at a lower infusion rate. Consider medication with antihistamines, acetaminophen, and corticosteroids. Discontinue SYLVANT® if the patient does not tolerate the infusion following these interventions.

Administer SYLVANT® in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.

Gastrointestinal (GI) Perforation – Use with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with symptoms that may be associated with or suggestive of GI perforation.

Adverse Reactions – The most common adverse reactions (>10% compared to placebo) in the MCD clinical trial were rash (28%), pruritus (28%), upper respiratory tract infection (26%), increased weight (19%), and hyperuricemia (11%).

Drug Interactions Cytochrome P450 (CYP450) Substrates – Upon initiation or discontinuation of SYLVANT®, in patients being treated with CYP450 substrates with narrow therapeutic index, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) as needed and adjust dose. Exercise caution when SYLVANT® is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).

Please click here to read full Prescribing Information for SYLVANT®.

cp-61150v1